Drug Profile

ADX 038

Alternative Names: ADX-038

Latest Information Update: 18 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ADARx Pharmaceuticals
Class Oligonucleotides; Small interfering RNA
Mechanism of Action RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Paroxysmal nocturnal haemoglobinuria

Most Recent Events

07 Nov 2025 Efficacy and adverse events data from a phase I trial in Paroxysmal nocturnal haemoglobinuria released by ADARx Pharmaceuticals
25 May 2025 ADARx Pharmaceuticals plans phase-II trial for Membranous glomerulonephritis and IgA nephropathy in July 2025 (Unspecified) (NCT06989359),
25 May 2025 ADARx Pharmaceuticals plans a phase II trial for Dry age-related macular degeneration (SC) in August 2025 (NCT06990269)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com